Shingrix costs 600,000 won

4 times higher than the existing vaccine

GSK and GC Pharma officially signed a joint sales contract for shingles vaccine

300,000 won is expected for one vaccination

The inoculation price of Shingrix, a shingles vaccine scheduled to be supplied in December, is expected to be around 600,000 won.

 

It is four to five times the existing inoculation price.

 

According to the pharmaceutical industry on the 15th, GSK and GC Pharma recently officially signed a domestic joint sales contract for Shingrix.

 

The two companies agreed to supply the next-generation shingles vaccine at around 160,000 won.

 

The inoculation price reflecting the supply price is expected to be around 300,000 won.

 

In the case of Shingrix, considering that immunity is completed with two vaccinations, the total vaccination price to be paid by the patient is around 600,000 won.

 

The existing vaccines MSD Zostavax and SK Bioscience SKY Zoster were sold for 150,000 won to 200,000 won at the front-line opening price.

 

In the case of Shingrix, vaccination prices have been set at four to five times the level of existing vaccines.

 

GSK and GC Pharma plan to start distributing Shingrix nationwide in December.

 

The first volume is 360,000 degrees, which can fit 180,000 people.

 

GSK obtained Shingrix permission from the Ministry of Food and Drug Safety in September last year.

 

It was originally planned to be released in February this year, but the schedule was delayed day by day.

 

Shingrix is a vaccine used to prevent herpes zoster in adults over the age of 50 and immunocompromised people over the age of 18.

 

When Shingrix is released, it is expected to be the third shingles vaccine in Korea after MSD Zostavax and SK Bioscience SKY Zoster.

 

It is evaluated that the effect of preventing shingles confirmed in clinical trials is superior to that of the two existing vaccines.

 

In Shingrix clinical trials (ZOE-50) for adults over the age of 50, the effect of preventing shingles was 97% at 3.2 years after vaccination.

 

In clinical trials (ZOE-70) for those aged 70 or older, it was 90% at 3.7 years after vaccination.

 

In the case of Zostavax, a competitive product, it has a preventive effect of 51% for those over 50 and 41% for those over 70.

 

SKY Zoster demonstrated Zostavax and specific heat in clinical practice.

 

It is analyzed that there is no significant difference from Zostavax in terms of prevention rate.

 

GC Pharma has experience in co-selling MSD's herpes zostavax vaccine in the past.

 

GC Pharma co-sold Zostavax for eight years until 2020 through a contract extension once after signing a co-promotion contract with MSD since 2013.

 

In the process, Zostavax has grown into a large item with annual sales of 80 billion won.

 

However, SK Bioscience launched its competitive product SKY Zoster at the end of 2017, and sales have decreased significantly since 2020 as the overall market size has shrunk due to the prolonged Corona crisis.

 

According to IQVIA, a pharmaceutical market research firm, Zostavax sales last year amounted to 27 billion won, down 68% in four years from 83.7 billion won in 2017.

 

This year, sales were only 11.6 billion won until the first half of the year.

 

The pharmaceutical industry expects Shingrix to lead the domestic shingles vaccine market to rebound.

 

In the global market, Shingrix's sales, which had already been dampened by the Corona crisis, began to recover in the second half of last year.

 

In the first half of this year, Shingrix's global sales were £1.429 billion, more than doubling compared to the same period last year.